Back to User profile » Professor alper sevinc
Papers published by Professor alper sevinc:
![Video](assets/img/article_icons/video.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey – NOTES study
![](assets/img/youtube_social_icon_dark.png)
![](http://img.youtube.com/vi/O_iMRc9mijY/1.jpg)
Yalcin Ş, Yildiz R, Dane F, Karaoğlu A, Öksüzoğlu B, Özyilkan Ö, Sevinç A, Özdemir F, Turna H, Uslu R, Ulay E
OncoTargets and Therapy 2018, 11:1223-1228
Published Date: 5 March 2018
![Video](assets/img/article_icons/video.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia
![](assets/img/youtube_social_icon_dark.png)
![](http://img.youtube.com/vi/uUDZRDek08g/1.jpg)
Sevinç A, Özkan M, Özet A, Dane F, Öksüzoğlu B, Işıkdoğan A, Özdemir F, Uncu D, Gümüş M, Evrensel T, Yaren A, Kara O, Tekin SB
OncoTargets and Therapy 2018, 11:419-426
Published Date: 18 January 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel
Kus T, Aktas G, Kalender ME, Demiryurek AT, Ulasli M, Oztuzcu S, Sevinc A, Kul S, Camci C
OncoTargets and Therapy 2016, 9:5073-5080
Published Date: 12 August 2016
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study
Aktas G, Kus T, Kalender ME, Sevinc A, Camci C, Kul S
OncoTargets and Therapy 2016, 9:1921-1926
Published Date: 1 April 2016
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Prognostic impact of initial maximum standardized uptake value of 18F-FDG PET/CT on treatment response in patients with metastatic lung adenocarcinoma treated with erlotinib
Kus T, Aktas G, Sevinc A, Kalender ME, Yilmaz M, Kul S, Oztuzcu S, Oktay C, Camci C
OncoTargets and Therapy 2015, 8:3749-3756
Published Date: 15 December 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure?
Kus T, Aktas G, Sevinc A, Kalender ME, Camci C
OncoTargets and Therapy 2015, 8:1341-1343
Published Date: 5 June 2015